Trial results offer clinically important information on the efficacy and safety of the combination therapy in CKD with type 2 diabetes.

Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage trial met its main goal.

The first phase includes industrial land allocation services, which will be provided through an investment map and by issuing operating licenses with annual notification and follow-up. The ...

New! Sign up for our free email newsletter.

President Trump's meeting with German Chancellor Friedrich Merz will take place amid a backdrop of tensions between the U.S. and Europe over trade and Ukraine.